A Study of Combination Therapy in NSCLC
NCT04544644
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
AK104+anlotinib
Sponsor
Chinese PLA General Hospital